3-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one | 728011-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one
• 英文别名: 3-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1H-indol-2-one
• CAS: 728011-24-3
• 化学式: C₁₆H₁₂F₃NO₄
• 分子量: 339.271
• InChiKey: CZDZAKZFLNAVMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one 、 4-(2-(4-tert-butylphenoxy)ethyl)morpholine 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以31%的产率得到3-{5-tert-butyl-2-[2-(morpholin-4-yl)ethoxy]phenyl}-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors

  摘要：

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.030
• 作为产物：
  描述：

  4-甲氧基苯基溴化镁 、 5-三氟甲氧基吲哚-2,3-二酮 以 四氢呋喃 为溶剂， 反应 2.0h， 以79.6%的产率得到3-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethoxy)-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors

  摘要：

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.030

文献信息

• Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors
  作者：Séverine Denoyelle、Ting Chen、Hongwei Yang、Limo Chen、Yingzhen Zhang、José A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2013.08.030

  日期：2013.11

  The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the elF2.GTP.MettRNAlviet ternary complex assembly and 345-tert-butyl-2-hydroxypheny1}-3-phenyl-1,3-dihydro-2Hindol-2-one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low uM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer. (C) 2013 Elsevier Masson SAS. All rights reserved.